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Abstract: In recent years, there has been increasing interest in dimeric molecules due to reports of their
promising therapeutic value in the treatment of numerous diseases (such as cancer, HIV, Alzheimer’s
and, malaria). Many reports in the literature have highlighted the ability of these molecules to interact
not only with specific biologic receptors but also to induce a biological response that more than
doubles the results of the corresponding monomeric counterpart. In this regard, flavonolignan dimers
or simply bi-flavonolignans are an emerging class of dimeric compounds that unlike bi-flavonoids,
which are very widespread in nature, consist of synthetic dimers of some flavonolignans isolated
from the milk thistle Silybum marianum [L. Gaertn. (Asteraceae)]. This mini-review will discuss
recent developments in the synthesis, characterization and antioxidant activity of new families of
flavonolignan dimers, in light of emerging medicinal chemistry strategies.
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1. Introduction
Flavonolignans are secondary metabolites present in a few plants (Asteraceae, Berberidaceae,
Chenopodiaceae, Flacourtiaceae, Fabaceae, Poaceae, and the Scrophulariaceae species) commonly used
in the human diet, of which consumption has increased considerably in recent years thanks to their
beneficial biological activity [1]. Pelter and Haensel [2] first proposed the generic name "flavonolignan"
for naturally occurring hybrid molecules that are biogenetically originated from ubiquitous flavonoids
and monolignols (namely, p-coumaryl, coniferyl and, sinapyl alcohol) [3–6].
Flavonoid portions, the flavonolignans isolated from plants, may initially be divided into four
types (Figure 1): flavanonol-, flavonol-, flavanone and flavone-type.Molecules 2019, 24, x 2 of 12 
 
 
Figure 1. Classification of naturally occurring flavonolignans. 
Flavonolignans have a broad structural diversity as a consequence of the C-C or C-O linkage of 
the C6C3 unit (monolignol unit) to the flavonoid nucleus in different positions, affording dioxane, 
furan, cyclohexane rings or simple ether side chains. In general, these compounds contain several 
chiral centers, hence they usually occur in nature into stereoisomer forms. By 2016, over forty 
flavonolignans, containing eight different flavonoid counterparts, had been isolated from over 
twenty species of plants [1]. 
The main source of flavonolignans is the milk thistle Silybum marianum (L. Gaertn. (Asteraceae)). 
A crude extract of its seeds, industrially manufactured and named silymarin [7,8], contains several 
flavonolignans such as silibinin [9] (as pair stereoisomers silybin A and silybin B), [10], isosilybin A 
and isosilybin B, silychristin A, 2,3-dehydrosylibin (A and B) [11] and silydianin (Figure 2). S. 
marianum enjoyed a period of high esteem in folk medicine as a liver tonic [12]. Its extracts were used 
to improve liver function, protect against liver damage and accelerate the regeneration of damaged 
liver cells. Clinical studies have confirmed the usefulness of standardized milk thistle extracts in cases 
of liver intoxication, cirrhosis and other chronic liver diseases related to alcohol abuse. Several 
decades ago, silibinin and other components of the silymarin complex were discovered to be 
beneficial in treating liver damage resulting from the consumption of toxic fungi, such as Amanita 
phalloides [13]. It has been recently demonstrated that silymarin inhibits the production of leukotriene 
which explains its anti-inflammatory effect and antibiotic action. Clinical tests confirm the positive 
effects found in the experimental studies [14]. 
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Flavonolignans have a broad structural diversity as a consequence of the C-C or C-O linkage of the
C6C3 unit (monolignol unit) to the flavonoid nucleus in different positions, affording dioxane, furan,
cyclohexane rings or simple ether side chains. In general, these compounds contain several chiral
centers, hence they usually occur in nature into stereoisomer forms. By 2016, over forty flavonolignans,
containing eight different flavonoid counterparts, had been isolated from over twenty species of
plants [1].
The main source of flavonolignans is the milk thistle Silybum marianum (L. Gaertn. (Asteraceae)).
A crude extract of its seeds, industrially manufactured and named silymarin [7,8], contains several
flavonolignans such as silibinin [9] (as pair stereoisomers silybin A and silybin B), [10], isosilybin A and
isosilybin B, silychristin A, 2,3-dehydrosylibin (A and B) [11] and silydianin (Figure 2). S. marianum
enjoyed a period of high esteem in folk medicine as a liver tonic [12]. Its extracts were used to improve
liver function, protect against liver damage and accelerate the regeneration of damaged liver cells.
Clinical studies have confirmed the usefulness of standardized milk thistle extracts in cases of liver
intoxication, cirrhosis and other chronic liver diseases related to alcohol abuse. Several decades ago,
silibinin and other components of the silymarin complex were discovered to be beneficial in treating
liver damage resulting from the consumption of toxic fungi, such as Amanita phalloides [13]. It has
been recently demonstrated that silymarin inhibits the production of leukotriene which explains its
anti-inflammatory effect and antibiotic action. Clinical tests confirm the positive effects found in the
experimental studies [14].Molecules 2019, 24, x 3 of 12 
 
 
Figure 2. Main flavonolignans from S. marianum (L. Gaertn. (Asteraceae)). 
The major component of silymarin is silibinin, which is an almost equimolar diasteromeric 
mixture of silybin A and silybin B, easily available due to its high proportion in silymarin (ca 30%). 
Isolation of both pure diastereomers in multigram quantities can be accomplished by a preparative 
HPLC method [10] or advanced chemo-enzymatic protocols [15,16]. In the past decade, the medicinal 
merits of silibinin have been extended to include the potential for preventing and treating various 
diseases, thanks to properties that include anti-cancer [17], neuroprotective [18,19], antiviral [20] and 
antifibrotic activities [21]. 
2. Bi-Flavonolignans: New Promising Synthetic Metabolite Dimers 
Bi-flavonolignans are an emerging class of dimeric compounds that unlike bi-flavonoids, which 
are very widespread in nature, consists of synthetic dimers of some flavonolignans. Synthetic bi-
flavonolignans have also been found to exhibit interesting antioxidant activities, at over twice the 
rate of their natural monomeric units. However, despite these attractive features, synthetic bi-
flavonolignans represent a poorly explored compound family within drug discovery. 
Even if the number of flavonolignan units available is naturally low, when coupled with the 
large number of possible permutations in the position and nature of inter-flavonolignan linkage, a 
considerable structural diversity within the bi-flavonolignan class could be provided. To date, there 
exist only a few different synthetic approaches and these typically generate compound collections 
that are based around a very limited range of structures. 
Today the only bi-flavonolignans reported in the literature are characterized by two 
flavonolignan units conjoined through an alkyl, alkoxy or phosphodiester-based linker. The high 
structural diversity of the silymarin component (Figure 2) makes the design of chemical 
modifications a difficult but appealing challenge. Below, the synthesis of known bi-flavonolignans 
will be discussed, focusing on the molecular diversity and their resulting anti-oxidant properties. 
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HPLC method [10] or advanced chemo-enzymatic protocols [15,16]. In the past decade, the medicinal
merits of silibinin have been extended to include the potential for preventing and treating various
diseases, thanks to properties that include anti-cancer [17], neuroprotective [18,19], antiviral [20] and
antifibrotic activities [21].
2. Bi-Flavonolignans: New Promising Synthetic Metabolite Dimers
Bi-flavonolignans are an emerging class of dimeric compounds that unlike bi-flavonoids,
which are very widespread in nature, consists of synthetic dimers of some flavonolignans.
Synthetic bi-flavonolignans have also been found to exhibit interesting antioxidant activities, at over
twice the rate of their natural monomeric units. However, despite these attractive features, synthetic
bi-flavonolignans represent a poorly explored compound family within drug discovery.
Even if the number of flavonolignan units available is naturally low, when coupled with the
large number of possible permutations in the position and nature of inter-flavonolignan linkage,
a considerable structural diversity within the bi-flavonolignan class could be provided. To date, there
exist only a few different synthetic approaches and these typically generate compound collections that
are based around a very limited range of structures.
Today the only bi-flavonolignans reported in the literature are characterized by two flavonolignan
units conjoined through an alkyl, alkoxy or phosphodiester-based linker. The high structural diversity
of the silymarin component (Figure 2) makes the design of chemical modifications a difficult but
appealing challenge. Below, the synthesis of known bi-flavonolignans will be discussed, focusing on
the molecular diversity and their resulting anti-oxidant properties.
2.1. Flavonolignan Dimers Linked by C-C and/or C-O Bridge
The first bi-flavonolignans were isolated only ten years ago from Gazek et al. [22,23]. In this paper,
the authors reported that the oxidation of natural silibinin in the presence of a stable radical such as
DPPH, prevents the evaluation of its radical scavenger mechanism of action due to the formation of
complex mixtures of high molecular weight products that are very difficult to separate. In order to
reduce the reactivity of natural silibinin, they studied methylated silibinin derivatives.
The methylation to hydroxyl at C-4′ ′ or C-7 (Figure 3) showed less reactivity than silibinin, about
30 and 80%, respectively. However, silibinin C-4′ ′ O-methylated only underwent a small slowdown of
oxidative processes, giving a mixture of oligomers always too difficult to purify [23]. Instead, using
silibinin O-methylated at C-7 and laccase-mediated oxidation with Trametes pubescens, bi-flavonolignans
1 and 2 (Figure 3) in a ratio of about 2:5 and with yields of 9% and 25%, respectively, were obtained [22].
The same products were obtained by an oxidation reaction based on K3Fe(CN)6 [23] with yields of
40 and 4%, respectively. It should be noted that the asymmetric products 1 and 2 were presumably
a mixture of four diastereoisomeric products, while the symmetric product 3 was a mixture of three
diasteroisomers. Interestingly, no significant results were obtained by applying the same catalyzed
laccase reaction to the O-methylated at C-4′ ′ silibinin (overactive substrate). An extensive theoretical
study [24] indicates that the site most susceptible to oxidative attack in the silibinin is the OH at C-4′ ′,
which loses a hydrogen and give rise to a radical with high spin density on the oxygen O-4′ ′ and on
the carbons C-1′ ′, C-3′ ′ and C-5′ ′. The dimerization process at ring E of the silibinin passes through
the formation of a phenyl-phenyl link between the two radicals in the ketone-like form, which then
undergoes tautomeric transformation to the enol form that is strongly favored by a thermodynamic
point of view. The whole process is more facilitated in apolar solvents, since polar ones do not promote
the formation of hydrogen bonds that stabilize the dimer form.
In the case of dehydrosilybin, both conformational and electronic point of views assumes that ring
E is very similar to the corresponding ring of silibinin. The hydroxyl group at carbon C-3 is the site
with the highest tendency to oxidation, with high spin density localized on O-3 and carbon C-3. If DHS
is O-methylated at C-5, C-7, and C-4′ ′, the corresponding dimer 5 is obtained by DPPH treatment
(Figure 4), the formation of which is thermodynamically favored in apolar solvents. It should be noted
Molecules 2019, 24, 108 4 of 11
that the formation of the bond does not follow a tautomeric reorganization, but ring C of one of the
two units, which loses flatness and has a simple bond between positions C-2 and C-3. Presumably,
the reaction gives a mixture of diastereoisomers which differ in the configuration to the chiral centers
C-2 and C-3 of the lower part, instead having configurations both R or both S at the C-7′ ′ and C-8′ ′
centers of the two flavonolignanic units (up to sixteen different compounds) [23].
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The methylation to hydroxyl at C-4′′ or C-7 (Figure 3) showed less reactivity than silibinin, about 
30 and 80%, respectively. However, silibinin C-4′′ O-methylated only underwent a small slowdown 
of oxidative processes, giving a mixture of oligomers always too difficult to purify [23]. Instead, using 
silibinin O-methylated at C-7 and laccase-mediated oxidation with Trametes pubescens, bi-
flavonolignans 1 and 2 (Figure 3) in a ratio of about 2:5 and with yields of 9% and 25%, respectively, 
were obtained [22]. The same products were obtained by an oxidation reaction based on K3Fe(CN)6 
[23] with yields of 40 and 4%, respectively. It should be noted that the asymmetric products 1 and 2 
were presumably a mixture of four diastereoisomeric products, while the symmetric product 3 was 
a mixture of three diasteroisomers. Interestingly, no significant results were obtained by applying the 
same catalyzed laccase reaction to the O-methylated at C-4′′ silibinin (overactive substrate). An 
extensive theoretical study [24] indicates that the site most susceptible to oxidative attack in the 
silibinin is the OH at C-4′′, which loses a hydrogen and give rise to a radical with high spin density 
on the oxygen O-4′′ and on the carbons C-1′′, C-3′′ and C-5′′. The dimerization process at ring E of the 
silibinin passes through the formation of a phenyl-phenyl link between the two radicals in the ketone-
like form, which then undergoes tautomeric transformation to the enol form that is strongly favored 
by a thermodynamic point of view. The whole process is more facilitated in apolar solvents, since 
polar ones do not promote the formation of hydrogen bonds that stabilize the dimer form. 
In the case of dehydrosilybin, both conformational and electronic point of views assumes that 
ring E is very similar to the corresponding ring of silibinin. The hydroxyl group at carbon C-3 is the 
site with the highest tendency to oxidation, with high spin density localized on O-3 and carbon C-3. 
If DHS is O-methylated at C-5, C-7, and C-4′′, the corresponding dimer 5 is obtained by DPPH 
treatment (Figure 4), the formation of which is thermodynamically favored in apolar solvents. It 
should be noted that the formation of the bond does not follow a tautomeric reorganization, but ring 
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Gavezzotti et al. [25] obtained the dimers 2 starting from silybin A and silybin B, selectively 
benzylated to the OH group at C-7 (Figure 4), in a reaction catalyzed by a laccase from Trametes 
versicolor. After de-O-benzylation the dimers 4aa and 4bb were obtained in 11% and 7% yields, 
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The dehydrosilybins methylated to the hydroxyl groups at C-3 and C-7, in the presence of
an oxidant such as DPPH, leads to the formation of 6 (a mixture of the two enantiomers and the
meso-isomer) and 7 dimers (a mixture of the two pairs of enantiomers), with low yields and dependent
on the solvent used. If the hydroxyl groups at C-3 and C-7 are free, a more abundant mixture is
obtained but difficult to purify. The formation of such dimers had been correctly predicted by the
theoretical study. It is important to emphasize that the dimers are not stabilized by conjugation but by
the formation of intramolecular hydrogen bonds, partly counteracted by steric repulsion.
Gavezzotti et al. [25] obtained the dimers 2 starting from silybin A and silybin B, selectively
benzylated to the OH group at C-7 (Figure 4), in a reaction catalyzed by a laccase from Trametes versicolor.
After de-O-benzylation the dimers 4aa and 4bb were obtained in 11% and 7% yields, respectively.
By the same reaction, the silydianin dimer 8 (Figure 5) starting from the unprotected corresponding
flavonolignan, and the benzylated silychristine dimer 9 were also obtained [25].Molecules 2019, 24, x 6 of 12 
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Classical reaction with p- or m-xylylene dibromide in the presence of K2CO3 was used to obtain
dimers 12 and 13 with a more rigid xylenyl linker. Redox behavior and cytotoxicity on human
umbilical vein endothelial cells, normal human adult keratinocytes, mouse fibroblasts (BALB/c 3T3)
and human liver hepatocellular carcinoma cell lines (HepG2) were evaluated. In particular, the results
obtained by DPPH and inhibition of microsomal lipoperoxidation assays reported that silybin dimers
showed better activity than the monomers, on the contrary, the 2,3-dehydrosilybin dimer 11 presented
weaker antioxidant/antilipoperoxidant activity than its monomer (DHS). Conversely, regarding the
cytotoxicity aspect, the silybin dimers were more cytotoxic than the parent compound. Instead,
the 2,3-dehydrosilybin dimer showed weaker cytotoxicity than the monomer [27].
Recently, a new family of flavonolignan dimers has been proposed by Romanucci et al. [28]:
Phosphate-Linked Silibinin dimers (PLSd). Inspired by oligoflavonoid structures [29] and exploiting
phosphoramidite chemistry [30–33], they reported an efficient synthetic strategy to obtain new silibinin
dimers in which the monomeric units are linked through phosphodiester bonds (Figure 7).
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analyses and purification, the products were converted into the corresponding sodium salts leading
to the phosphodiester derivatives 14–16 (20%) in good yields (15–20%). PLSd have a good water
solubility (more than 20 mgL−1) under circumneutral pH values, whereas the silibinin was found to
be very poorly soluble (less than 0.4 mgL−1). Their antioxidant properties were evaluated by different
approaches and preliminary antioxidant tests (DPPH test [36,37]) showed a pronounced increase in
the activity of the dimers compared to to the silibinin. The anti-oxidant behavior of dimers 14–16 were
also investigated towards two different ROS, 1O2 and OH radical. The ability to scavenge 1O2 in H2O
was tested. Despite a similar reactivity for both dimers and silibinin, a higher reactivity towards the
OH radical (about twice) was estimated for the dimers 14 and 16 with respect to the silibinin with a
second order rate constant major than 1.5 × 1010 M−1·s−1. A value very similar to that reported for a
known potent antioxidant as quercetin. The PLSd showed a very low toxicity towards HepG2 cells
(even for long exposure times). The cytoprotective effect was evaluated on HepG2 cells and using the
DCFH-DCF assay where the oxidative stress was carried out by Xanthine/Xanthine oxidase (X/XO)
system. All the dimers showed a strong ability to scavenge most of the free radicals generated by
X/XO on HepG2 cells and in all cases more efficiently than silibinin [29].
3. Conclusions
Dimer or oligomer molecules often exhibit enhanced biological activity relative to the simple
monomer units and their pharmacokinetic parameters are improved [38,39]. Sometimes, an entirely
new biological entity is created by dimerization or oligomerization of different building blocks [40–44].
Contrary to many flavonoids that exist naturally as dimer forms, the flavonolignan dimers are only
synthetic. The source of flavonolignan monomeric units is the milk thistle Silybum marianum (L. Gaertn.
(Asteraceae)), whose seed extract is named silymarin. In the last ten years, the synthetic approaches
reported are different and range from chemical to enzymatic strategies. Initially, flavonolignan dimers
have been observed in studies to understand the anti-oxidant (or pro-oxidant) activity of the different
OH functions of flavonolignans as silibinin, silydianin or silychristin and theoretical studies have
been conducted [22–26]. Starting from different O-alkylated (O-methyl or O-benzyl) flavonolignans,
the reactivity profile of different OH groups was outlined. The focus of these studies was the reactivity
of different OH groups in the presence of stable radical or enzymatic conditions and consequently,
biological screening was not accomplished for dimers obtained.
In 2014, Vavrˇíková et al. [27] reported the chemo-enzymatic synthesis of silibinin, silybin A
and/or silybin B and 2,3-dehydro-silybin linked by different length spacers. This was one of the
first syntheses starting from the two diastereoisomers, silybin A and silybin B [35]. Redox behavior
and cytotoxicity on different line cells were evaluated and, in general, silibinin dimers showed better
activity than the monomers, although the 2,3-dehydrosilybin dimer showed weaker antioxidant
activity than its monomer. Conversely, the silibinin dimers were more cytotoxic than the parent
compound. Instead, the 2,3-dehydrosilybin dimer showed weaker cytotoxicity than the monomer.
It was recently reported that using inspiration from oligoflavonoid structures and the exploitation of
phosphoramidite chemistry, resulted in an efficient synthetic strategy to obtain new silibinin dimers in
which the monomeric units are linked through phosphodiester bonds: the Phosphate-Linked Silibinin
dimers (PLSd) [28]. New dimers (PLSd) presented a good water solubility (more than 20 mg·L−1)
under circumneutral pH values, whereas the silibinin was found to be poorly soluble (less than
0.4 mg·L−1). All dimers showed a strong ability to scavenge most of the radicals more efficiently
than silibinin as well as a very low toxicity towards HepG2 cells (even for long exposure times).
The combination of high antioxidant activity with low toxicity as well as their good water solubility,
make the PLSd promising synthetic metabolites in the large class of polyphenols.
These last two strategies offer the possibility to design dimers with a high molecular diversity,
both in the nature of the building blocks and the length of the spacer.
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